XOMA was laying off folks in Berkeley back in Winter of this year. I am not even sure if they are still around. Anyhow, I do think that development/manufacturing of monoclonal antibody-based therapeutics has a lucrative future - So I am not sure what's wrong here, maybe the mgmt has issues
There are no replies in this thread yet. Be the first to post a reply below: